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Abstract
Background: Physical activity level and overweight have shown associations with mental health problems but it is not
known whether the risk of mental health problems due to overweight varies by physical activity. We examined joint
association of physical activity and overweight with subsequent psychotropic medication among 40–60-year-old
employees.
Methods: The questionnaire survey data were derived from Helsinki Health Study baseline postal questionnaires in
2000–02 among employees of the City of Helsinki aged 40–60 years (n = 8960, response rate 67 %). Baseline survey
data were linked with prospective register data on prescribed psychotropic medication (ATC-codes N05 and N06,
except N06D) among those with written consent (74 %) for such linkage. The analyses included 6169 responders
(78 % women, corresponding to the target population). We divided participants into six groups according to their
baseline self-reported body mass index and leisure-time physical activity using physically highly active normal-weight
participants as a reference group. We used Cox regression analysis adjusted for age, gender, psychotropic medication
prior to baseline, and socioeconomic position, marital status, working conditions, limiting long-standing illness, alcohol
use, and smoking.
Results: At baseline, 49 % were overweight and 23 % were physically inactive. After adjusting for age and gender,
inactive normal-weight (hazard ratio (HR) 1.3, 95 % CI 1.1–1.5), moderately active overweight (HR 1.3, 95 % CI 1.1–1.5)
and inactive overweight (HR 1.4, 95 % CI 1.2–1.6) had higher risk for any psychotropic medication compared with
group of highly active normal-weight. After adjusting for prior medication, only the inactive overweight group had
higher risk (HR 1.4, 95 % CI 1.2–1.6). Other covariates made but a minor contribution to the examined associations.
For antidepressants the associations were somewhat stronger than for sedatives.
Conclusions: Both normal-weight and physical activity help prevent psychotropic medication but physical activity
dominates the association over normal-weight.
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Background
Mental health problems are increasing around the world
and are topical issues from public health perspective [1]
and better treatment might be beneficial to decreasing
costs of mental health problems. Psychotropic medica-
tion is widely used in general population of various
countries [2–4] and there is evidence that prescribed psy-
chotropic medication is more common among women
than men [3, 4]. Poor mental health further is a major
cause for work disability and disability-retirement [5].
Physical inactivity and overweight are associated with
mental health problems [6–9]. Additionally, physical in-
activity alone is a public health risk factor and a number
of studies have showed that leisure-time physical inact-
ivity increases the risk of various diseases and mortality
[10–13]. Leisure-time physical activity may also be im-
portant in reducing the risk of mental health problems
[14] and even small amounts of physical activity may pro-
tect against depression [7]. Furthermore, some studies
suggest that higher amounts of physical activity may
show further benefits for mental health [6, 15]. Physical
activity has been successfully used to treat depression
[16–18] and some anxiety disorders [16] although the
evidence is still weak. A study of six European popu-
lations [8] showed that obese people had more mood
disorders and comorbid mental disorders compared to
normal-weight population. The association between
high BMI and mental health problems is seen clearest
in post-traumatic stress disorder and in different
anxiety disorders [9].
Earlier longitudinal study from the same data showed
that physical activity is likely to be beneficial for self-
reported mental health functioning among both normal-
weight and overweight adults after a follow-up of 5 to
7 years [19]. Furthermore, a cross-sectional study of phys-
ical activity and overweight with health-related quality of
life showed that physical activity might be more important
than normal-weight for health-related quality of life [20].
We still lack studies of joint-association of physical activity
and overweight with subsequent mental health using
objective register based measures such as psychotropic
medication.
The aim of this study was to examine joint association
of leisure-time physical activity and overweight with sub-
sequent psychotropic medication. The contribution of
prior medication and other key covariates such as smok-
ing, drinking problems, limiting long-standing illness,
socioeconomic position, employment status, and marital
status to the association was also examined, because they
have been associated with mental health in previous
studies [21–24]. We expected that normal-weight and
high physical activity is the best protection against mental
health problems and psychotropic medication. Based on
previous study [6] we further expected that high physical
activity might protect against psychotropic medication
also among the overweight.
Methods
The questionnaire survey data were derived from the
Helsinki Health Study baseline postal questionnaires in
2000–02. Participants were employees of the City of
Helsinki, Finland, aged 40–60 years. There were 8960
responders (response rate 67 %) of whom 78 % were
women. The response rate was somewhat lower among
men, in younger age groups, lower occupational classes
and those with long sickness absence. The data were
linked to the register of prescribed psychotropic medica-
tion from the Social Insurance Institution of Finland.
Seventy-four percent of participants gave permission for
linkages and non-response analysis showed that non-
response and non-consent unlikely biased results [25, 26].
The follow-up started at the day of returning the question-
naire and ended to first psychotropic medication purchase
or death. The maximum follow-up time was 7.8 years and
mean follow-up time was 6.4 years (SD 2.45). Those with
psychotropic medication at baseline (n = 319) or with
missing information on leisure time physical activity
(n = 43), BMI (n = 47) or other covariates (n = 27)
were excluded. The analyses included 6169 responders
and 78 % on those were women. The ethics commit-
tees of the Department of Public Health, University of
Helsinki and health authorities of the City of Helsinki
have approved the Helsinki Health Study.
Physical activity
The participants were asked about the average weekly
time they spent in leisure-time physical activity (commut-
ing included) within the last 12 months. They were first
asked to estimate the intensity of their physical activity
compared to common activities: walking, brisk walking,
jogging, and running, or activities equivalent to these.
After that they were asked to estimate on average how
much time they spent in each intensity grade in 1 week.
Based on responds of leisure-time physical activity, an ap-
proximate metabolic equivalent (MET) value was calcu-
lated [27]. The average MET hours of leisure-time
physical activity in 1 week were calculated by multiplying
time used weekly by the estimated MET value of the each
intensity grade [28] and then summing all four MET
values together. The participants were then grouped into
inactive, moderately active, and highly active groups and
as cut-off points we used the recommended levels of phys-
ical activity [29]. The physically inactive group did under
14 MET hours weekly and it corresponds approximately
to 1000 kcal per week or less. Moderately active
group did 14–30 MET hours per week (approximately
1000–2000 kcal). Highly active group did over 30
MET hours (approximately over 2000 kcal) of physical
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activity per week, which is the recommended level for
healthy weight maintenance [29].
Body mass index
Body mass index was calculated from self-reported weight
(kg) and height (m). Participants whose BMI was under or
equal to 25 kg/m2 were grouped as normal-weight and
whose BMI was over 25 kg/m2 were grouped as over-
weight. Ca 1 % (n = 59) of participants were underweight
(BMI under 18,5 kg/m2) and those were excluded from the
sample but no effect to the association was found and
underweight participants were retained in the final sample.
Psychotropic medication
Psychotropic medication data from Social Insurance
Institution of Finland were classified according to the
Anatomical Therapeutic Chemical (ATC) classification
system [30]. ATC codes N05 and N06 (except N06D
which is medication for dementia) were included to any
psychotropic medication. We also examined antidepres-
sants (N06A) and anxiolytics and sedatives (N05B and
N05C) separately but groups were not mutually exclu-
sive. The follow up started at the day of returning the
questionnaire and ended to first psychotropic medica-
tion purchase or death. Mortality data were derived from
the registers of Statistics Finland.
Covariates
Covariates derived from the baseline questionnaire in-
cluded age, gender, marital status, physical and mental
strenuousness of work, smoking, drinking problems, and
limiting long-standing illness (LLI). Socioeconomic pos-
ition was derived from the employer’s registers and prior
psychotropic medication was derived from the register
of Social Insurance Institution of Finland. At baseline
age was classified into five groups: 40, 45, 50, 55 and
60 years. Information on prior psychotropic medication
3 years preceding baseline were included. Socioeconomic
position was measured by four occupational classes:
managers/professionals, semi-professionals, routine non-
manual employees, and manual workers [31]. Marital
status was dichotomized to partnership or no partner-
ship. Physical strenuousness of work was dichotomized
to light or heavy. Similar procedure was followed for
mental strenuousness of work. Smoking was divided to
smokers and non-smokers. Alcohol use was measured
by CAGE questionnaire, which describes drinking prob-
lems [32]. LLI was dichotomized into those reporting
any limiting long-standing illness and those not report-
ing LLI.
Statistical methods
We divided participants into six groups according to
their body mass index and leisure-time physical activity:
(1) inactive (under 14 METs) and normal-weight
(BMI ≤ 25 kg/m2), (2) moderately active (14–30 METs)
normal-weight, (3) highly active (over 30 METs) normal-
weight, (4) inactive overweight (BMI > 25 kg/m2), (5)
moderately active overweight, and (6) highly active over-
weight. The group of active normal-weight participants
was used as a reference group in all the analyses. Propor-
tions and 95 % confidence intervals for subsequent psy-
chotropic medication was first calculated. Cox regression
analysis was then used to examine the effect of covariates
and to calculate hazard ratios (HR) and their 95 % confi-
dence intervals (95 % CI). Men and women were in the
pooled data adjusting for gender because there was no sig-
nificant difference between genders (p = 0.44 for inter-
action). In model 1 age and gender were adjusted for. In
addition to covariates in model 1, in model 2 prior medi-
cation was adjusted for. In model 3 covariates in model 2
and socioeconomic position, marital status, and physical
and mental strenuousness at work were adjusted for. In
model 4 covariates in model 2 and smoking, drinking
problems, and LLI were adjusted for. We used IBM SPSS
Statistics version 22.0 for mac.
Results
At baseline, 19 % were physically highly active and
normal-weight and 18 % were physically inactive and
overweight (Table 1). During the follow-up, 30 % of partic-
ipants had at least one reimbursed purchase of any psy-
chotropic medication. Every fifth had antidepressant
purchases and only slightly fewer had sedative purchases.
Thirty-two percent of those who had any purchases of
psychotropic medication purchased both sedatives and
antidepressants. Exclusively antidepressant purchases were
35 % and exclusively sedatives 29 % of all psychotropic
medication purchases. Nineteen percent of participants
had had psychotropic medication within the last 3 years
before the baseline survey.
Psychotropic medication tended to be more common in
physically inactive overweight (34 %, 95 % CI 30.4–36.6)
and normal-weight (33 %, 95 % CI 29.3–37.1) than in the
highly active overweight (25 %, 95 % CI 22.6–28.1) and
normal-weight (27 %, 95 % CI 24.7–29.3) groups (Table 2).
The patterns were similar for antidepressants and
sedatives.
In age and gender adjusted model the inactive normal-
weight (HR 1.3, 95 % CI 1.1–1.5), moderately active
overweight (HR 1.3, 95 % CI 1.1–1.5), and inactive over-
weight (HR 1.4, 95 % CI 1.2–1.6) had higher risk of psy-
chotropic medication compared with the highly active
normal-weight, however, the highly active overweight
were not at increased risk (HR 1.0, 95 % CI 0.9–1.2)
(Table 3). Adjusting for prior medication before baseline
attenuated the associations after which only the inactive
overweight group had a significantly higher risk (HR 1.4,
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95 % CI 1.2–1.6) for any psychotropic medication.
Adjusting for covariates in model 3 had only a small
effect compared with model 2, but adjusting for LLI,
smoking, and drinking problems (model 4) further atten-
uated the associations. However, the inactive overweight
group still had a higher risk of psychotropic medication
(HR 1.2, 95 % CI 1.0–1.4).
For antidepressant medication the associations were
similar although slightly stronger than for the any psycho-
tropic medication. After adjustment for prior medication
the moderately active overweight, inactive normal-weight
and the moderately active and inactive overweight groups
had increased risk of antidepressant medication. After ad-
justment for baseline smoking, drinking problems and LLI
(model 4), those physically inactive normal-weight (HR
1.3, 95 % CI 1.1–1.6) and overweight (HR 1.4, 95 % CI
1.1–1.6) had a higher risk of antidepressant medication.
For sedative medication the association was weaker than
for antidepressants. Overweight was associated with
increased risk of sedative medication among physically
inactive (HR 1.3, 95 % CI 1.1–1.6) and moderately active
(HR 1.2, 95 % CI 1.0–1.5) after adjusting for age and gen-
der. After adjusting for prior medication the association
remained only for the inactive overweight group. After full
adjustments (model 4) no associations remained.
Discussion
In this study we examined joint-association of physical
activity and overweight with subsequent psychotropic
medication over a follow-up of around 8 years.
Main findings were as follows:
(1)Both normal-weight and physical activity are
associated with lower risk of psychotropic
medication but physical activity dominates the
association over normal-weight.
(2)Joint association of physical activity and overweight
were stronger with antidepressants than sedatives
The results of our study confirm results from pre-
vious longitudinal [19, 33] and cross-sectional [20]
studies with self-reported measures of mental health.
We conducted the analyses also for antidepressants and
sedatives, which are the two main groups of psycho-
tropic medication. Associations were quite similar to
any psychotropic medication but antidepressants had a
stronger association than sedatives. Unfortunately, we
do not have information on which mental disorder the
medication was prescribed for. There is comorbidity
between depression and anxiety [34] and antidepres-
sants are also prescribed for anxiety disorders [35].
However, previous studies on physical activity and
mental health problems have shown especially an
association with depression [17]. We also conducted
the analyses excluding those with both antidepressant
and sedative purchases and it made a minor contribu-
tion to the examined associations.
Table 1 Baseline participant characteristics
Men (%/n) Women (%/n) All (%/n)
% (n) % (n) % (n)
Age (mean) 50.1 49.2 49.4
Overweight (BMI > 25 kg/m2) 60.3 45.7 48.8
Activity groups
Highly active 41.8 36.9 38.0
Moderately active 33.3 40.1 38.6
Inactive 25.0 22.9 23.4
Weight/activity groups
Highly active
normal-weight
19.1 23.6 22.6
Moderately active
normal-weight
13.2 21.1 19.4
Inactive normal-weight 7.4 9.6 9.1
Highly active overweight 22.7 13.3 15.4
Moderately active overweight 20.0 19.0 19.2
Inactive overweight 17.6 13.4 14.3
Medication during follow-up
Any 22.8 31.6 29.7
Antidepressant 15.6 21.3 20.1
Sedatives 14.6 19.3 18.3
Prior medication
Any 14.0 20.9 19.4
Antidepressant 6.7 10.5 9.6
Sedatives 8.7 13.0 12.1
Work physical strenousness
Light 85.2 62.1 67.1
Heavy 14.8 37.9 32.9
Work mental strenousness
Light 85.4 86.6 86.3
Heavy 14.6 13.4 13.7
Marital status (in a relationship) 78.4 69.0 71.1
Sosioeconomic position
Manual worker 25.9 11.1 14.3
Routine non-manual 9.4 41.2 34.3
Semi-professional 19.9 19.4 19.5
Managers/professionals 44.8 28.4 32.0
Limiting long-standing
illness (LLI)
16.2 16.3 16.3
Drinking problems (cage) 23.3 15.2 16.9
Smoking 25.4 21.6 22.4
n 21.7 (1338) 78.3 (4831) 100 (6169)
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Overall, the associations in this study were relatively
weak but still relevant from public health perspective.
Mental health problems are commonly occurring [1]
and promoting physical activity among middle-aged em-
ployees may be useful for preventing mental health
problems. Association between overweight or obesity
and mental health problems are reciprocal [36] and in
our study we only examined the obesity to mental health
pathway. Although our study showed that overweight is
unlikely to notably affect the risk of mental health prob-
lems, normal-weight has plenty of other considerable
benefits for health such as better physical functioning.
A recent prospective study from United States [33]
showed that cardiorespiratory fitness is more important
than fatness in reducing depressive symptoms. Increas-
ing physical activity is the only way to improve cardiore-
spiratory fitness thus those highly active in our study
likely have better fitness than their less active counter-
parts which may also contribute to the differences found
in psychotropic medication purchases. Previous review
[7], however, concluded that even low doses of physical
activity are beneficial in terms of depressive symptoms,
supporting the view that there are positive effects of
physical activity independent of fitness on mental health.
Table 2 Prevalence of first psychotropic medication purchases (%) during the follow-up
n Any (%) Antidepressants (%) Sedatives (%)
All 6169 29.7 (28.6–30.9) 20.1 (19.1–21.1) 18.3 (17.3–19.3)
Highly active normal-weight 1397 27.0 (24.7–29.3) 17.3 (15.3–19.2) 16.3 (14.4–18.3)
Moderately active normal-weight 1198 30.4 (27.8–33.0) 20.2 (17.9–22.5) 19.5 (17.3–21.8)
Inactive normal-weight 561 33.2 (29.3–37.1) 23.5 (20.0–27.0) 19.8 (16.5–23.1)
Highly active overweight 947 25.3 (22.6–28.1) 16.8 (14.4–19.2) 15.5 (13.2–17.8)
Moderately active overweight 1185 31.3 (28.7–34.0) 21.4 (19.1–23.8) 19.4 (17.2–21.7)
Inactive overweight 881 33.5 (30.4–36.6) 23.7 (20.9–26.5) 20.3 (17.7–23.0)
Table 3 Hazard ratios for psychotropic medication purchases according to joint association of physical activity and BMI
All Model 1 Model 2 Model 3 Model 4
Highly active normal-weight 1.00 1.00 1.00 1.00
Moderately active normal-weight 1.17 (1.01–1.35) 1.15 (0.99–1.33) 1.15 (0.99–1.33) 1.09 (0.94–1.26)
Inactive normal-weight 1.28 (1.07–1.53) 1.21 (1.01–1.44) 1.20 (1.04–1.44) 1.15 (0.96–1.37)
Highly active overweight 1.01 (0.85–1.19) 1.00 (0.85–1.18) 1.01 (0.85–1.19) 0.96 (0.82–1.14)
Moderately active overweight 1.27 (1.10–1.48) 1.15 (0.99–1.34) 1.15 (0.99–1.34) 1.08 (0.93–1.26)
Inactive overweight 1.41 (1.20–1.65) 1.38 (1.18–1.62) 1.37 (1.17–1.61) 1.21 (1.04–1.42)
Antidepressants Model 1 Model 2 Model 3 Model 4
Highly active normal-weight 1.00 1.00 1.00 1.00
Moderately active normal-weight 1.21 (1.01–1.45) 1.21 (1.01–1.44) 1.20 (1.00–1.43) 1.15 (0.97–1.38)
Inactive normal-weight 1.45 (1.17–1.79) 1.38 (1.12–1.71) 1.37 (1.11–1.67) 1.31 (1.06–1.63)
Highly active overweight 1.06 (0.86–1.29) 1.06 (0.87–1.30) 1.07 (0.87–1.31) 1.03 (0.84–1.25)
Moderately active overweight 1.39 (1.16–1.66) 1.25 (1.05–1.50) 1.26 (1.05–1.51) 1.19 (1.00–1.43)
Inactive overweight 1.59 (1.32–1.91) 1.55 (1.29–1.87) 1.53 (1.27–1.85) 1.36 (1.13–1.64)
Sedatives Model 1 Model 2 Model 3 Model 4
Highly active normal-weight 1.00 1.00 1.00 1.00
Moderately active normal-weight 1.20 (1.00–1.44) 1.19 (0.99–1.43) 1.18 (0.99–1.42) 1.15 (0.95–1.38)
Inactive normal-weight 1.24 (0.99–1.56) 1.15 (0.91–1.44) 1.14 (0.91–1.43) 1.09 (0.87–1.37)
Highly active overweight 0.99 (0.80–1.21) 0.94 (0.76–1.16) 0.96 (0.78–1.18) 0.93 (0.76–1.15)
Moderately active overweight 1.23 (1.02–1.47) 1.12 (0.93–1.35) 1.13 (0.93–1.36) 1.05 (0.87–1.27)
Inactive overweight 1.32 (1.08–1.61) 1.28 (1.05–1.56) 1.27 (1.04–1.55) 1.14 (0.93–1.39)
Model 1 age and gender
Model 2 age, gender, and prior medication
Model 3 age, gender, prior medication, socioeconomic position, marital status, work mental and physical strenuousness
Model 4 age, gender, prior medication, limiting long-standing illness, drinking problems, and smoking
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Physical activity increases e.g. several neurotransmitters
such as serotonin and dopamine which may protect
especially against depression [37].
Mental health problems may also contribute to physical
inactivity, and in addition, some psychotropic medication
tends to increase body weight [38]. We were interested in
joint association between physical activity and overweight
with psychotropic medication in a follow-up and therefore
we excluded those with baseline psychotropic medication
and adjusted for previous medication in the analyses. We
conducted the analyses excluding those with prior psycho-
tropic medication within the last three years before the
baseline survey. The analyses showed that the association
were similar to those with previous medication adjusted
for (data not shown). Furthermore, those with drinking
problems have more anxiety and depression symptoms
[39] and economic difficulties and socioeconomic position
are also associated with mental health problems [40]. We
adjusted these as well as other key covariates, however,
more detailed control analyses showed that LLI attenuated
the association the most. Some LLI may restrict physical
activity and also increase the body weight and further con-
tribute to mental health problems.
Additional sensitivity analyses were made. We used dif-
ferent cut-off points for body mass index and physical ac-
tivity. We examined obesity (30 kg/m2) and also classified
BMI groups as well as physical activity according to ter-
tiles. Different cut-off points made a minor contribution
to the examined associations suggesting that the associa-
tions are not sensitive to the cut-off points used (data not
shown). In addition, we used defined daily dose (DDD) of
365 as outcome reflecting more severe problems in mental
health. Thirty-six percent of those having any psycho-
tropic medication had DDD over 365. We also divided
psychotropic medication purchases to three categories: no
purchases, 1 to 2 purchases, and 3 or more purchases.
Sixty-three percent of those having any psychotropic
medication had three or more purchases. However, these
additional analyses with more severe outcomes showed
similar associations with the first purchase as the outcome
(data not shown).
The strengths of this study include a prospective de-
sign and a large sample of middle-aged women and
men. Additionally, complete national register data of
psychotropic medication purchases linked with the sur-
vey data, is strength. We excluded those with the base-
line medication and adjusted for prior medication as
well as several other covariates.
The limitations of this study include self-reported
body mass index and leisure-time physical activity.
People tend to overestimate physical activity and height
and underestimate weight [41]. Despite of underestima-
tion, self-reported BMI is an adequate predictor of asso-
ciated health risks [42]. BMI cannot distinguish whether
the mass is from fat or from muscle but in middle-aged
population dominated by women this is likely not a
major concern. In leisure-time physical activity we used
cut-off points based on recommendation. Self-estimated
leisure-time physical activity was not validated, however,
no single physical activity questionnaire has proved
better than others for measurements of leisure-time
physical activity [43]. The psychotropic medication pur-
chases are not a direct measurement for mental health
because they have also other indications such as epi-
lepsy, pain, and sleep problems for several psychotropic
medicines. Some people with mental health problems
have no psychotropic medication and it is also unclear
whether people use the medicines they have purchased.
However, we were interested in the need of psychotropic
medication rather than if the participants had used the
medication purchased. The need of psychotropic medi-
cation is estimated when doctors decide to prescribe
psychotropic medication. We used only baseline infor-
mation of weight and leisure-time physical activity as
well as covariates and all these variables could change
during the follow-up. However, this is unlikely to result
in overestimating of the associations. Because 78 % of
participants were women and genders were combined in
the analyses, the results are dominated by the women.
However, the association were not significantly different
between genders.
Conclusions
Both normal-weight and physical activity may help pre-
vent psychotropic medication but physical activity domi-
nates the association. Higher amounts of physical activity
may show further benefits for mental health. Promoting
physical activity among middle-aged employees may prove
useful for preventing mental health problems.
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